You are here

  • Home
  • Archive
  • Volume 2, Issue Suppl 3
  • Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704)

Article metrics

Article menu

Download PDFPDF

Poster Presentation
Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704)

 

Online download statistics by month:

Online download statistics by month: December 2019 to January 2026

AbstractFullPdf
Dec 2019020
Jan 2020031
Feb 2020043
Mar 2020011
Apr 2020061
May 2020093
Jun 2020061
Jul 2020051
Aug 2020021
Sep 2020061
Oct 2020034
Nov 2020072
Dec 2020062
Jan 2021021
Feb 2021034
Mar 2021011
Apr 2021030
May 2021022
Jun 2021022
Jul 2021034
Aug 2021021
Sep 2021067
Oct 20210818
Nov 20210614
Dec 20210104
Jan 2022073
Feb 2022061
Mar 2022082
Apr 20220105
May 20220109
Jun 2022073
Jul 2022092
Aug 2022081
Sep 2022078
Oct 20220138
Nov 20220112
Dec 2022081
Jan 20230124
Feb 2023030
Mar 2023041
Apr 2023063
May 2023051
Jun 2023040
Jul 2023048
Aug 2023011
Sep 2023041
Oct 20230113
Nov 2023061
Dec 2023030
Jan 2024071
Feb 20240132
Mar 20240410
Apr 20240516
May 202401810
Jun 2024054
Jul 2024051
Aug 2024042
Sep 2024072
Oct 2024031
Nov 20240145
Dec 20240114
Jan 20250918
Feb 2025072
Mar 20250138
Apr 20250195
May 2025085
Jun 20250133
Dec 2025010
Jan 2026010
Total0442246